| CEO Name | James Hollingshead |
| Nationality | United Kingdom |
| Net Worth Estimation | $30 million |
James Hollingshead's estimated net worth of around $30 million primarily stems from his executive compensation, stock grants, and options at Insulet Corporation, as well as prior leadership roles at companies like Medtronic. Public SEC filings on insider transactions and awarded equity packages further substantiate this valuation.
James Hollingshead, CEO of Insulet Corporation in the healthcare sector, has an estimated net worth of $30,000,000. His net worth represents 25% of the maximum estimated CEO net worth ($90,000,000) and 300% of the minimum ($10,000,000) within this category.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
James Hollingshead Performance in Insulet Corporation
James Hollingshead, CEO of Insulet Corporation, exemplifies visionary leadership by driving innovation in medical devices, particularly insulin delivery systems. His decisive strategic initiatives and focus on operational efficiency have significantly enhanced the company's market position and financial performance. Under Hollingshead's tenure, Insulet has experienced robust growth, expanded its global footprint, and improved patient outcomes, solidifying its leadership in the diabetes care industry.
Latest News
Insulet Corporation Appoints Ashley McEvoy as CEO, Strengthens Leadership Team
Insulet named Ashley McEvoy, formerly executive VP at Johnson & Johnson, as President and CEO in April 2025, making it the only woman-led public company in Central Massachusetts. The company reported strong Q2 2025 revenue growth of 32.9% year-over-year, with McEvoy pushing global growth and innovation initiatives while promoting key executives to drive strategy and growth.
Source: http://investors.insulet.com/news/news-details/2025/Insulet-Appoints-Ashley-McEvoy-President-and-CEO/default.aspx